Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Open accessAbstract
BACKGROUND: High-dose chemotherapy plus autologous stem-cell transplantation has been the standard treatment for newly diagnosed multiple myeloma in adults up to 65 years of age. However, promising data on the use of combination therapy with lenalidomide, bortezomib, and dexamethasone (RVD) in this population have raised questions about the role and timing of transplantation. METHODS: We randomly assigned 700 patients with multiple myeloma to receive induction therapy with three cycles of RVD and then consolidation therapy with either five additional cycles of RVD (350 patients) or high-dose melphalan plus stem-cell transplantation followed by two additional cycles of RVD (350 patients). Patients in both groups received maintenance therapy with lenalidomide for 1 year. The primary end point was progression-free survival. RESULTS: Median progression-free survival was significantly longer in the group that underwent transplantation than in the group that received RVD alone (50 months vs. 36 months; adjusted hazard ratio for disease progression or death, 0.65; P<0.001). This benefit was observed across all patient subgroups, including those stratified according to International Staging System stage and cytogenetic risk. The percentage of patients with a complete response was higher in the transplantation group than in the RVD-alone group (59% vs. 48%, P=0.03), as was the percentage of patients in whom minimal residual disease was not detected (79% vs. 65%, P<0.001). Overall survival at 4 years did not differ significantly between the transplantation group and the RVD-alone group (81% and 82%, respectively). The rate of grade 3 or 4 neutropenia was significantly higher in the transplantation group than in the RVD-alone group (92% vs. 47%), as were the rates of grade 3 or 4 gastrointestinal disorders (28% vs. 7%) and infections (20% vs. 9%). No significant between-group differences were observed in the rates of treatment-related deaths, second primary cancers, thromboembolic events, and peripheral neuropathy. CONCLUSIONS: Among adults with multiple myeloma, RVD therapy plus transplantation was associated with significantly longer progression-free survival than RVD therapy alone, but overall survival did not differ significantly between the two approaches. (Supported by Celgene and others; IFM 2009 Study ClinicalTrials.gov number, NCT01191060 .).
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Randomized trials have consistently found similar overall survival with early ASCT versus delayed ASCT.
“However, randomized trials have consistently found similar OS with early ASCT (immediately following 4 cycles of induction therapy) versus delayed ASCT (at the time of relapse as salvage therapy).94,129–131”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [94]
The Results report similar four-year overall survival with early transplantation and RVD alone, and the Discussion says several earlier randomized trials found no significant overall-survival difference when salvage transplantation was allowed. But the Discussion also reports two studies finding an overall-survival benefit with first-line transplantation, so “consistently” overstates the evidence. This trial used three induction cycles, not four; neither passage provides a page number. (LLM, conf=0.87)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061 · see citing works
Self-citationInternational uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632 · see citing works
Self-citationA note on quantifying follow-up in studies of failure time
SCHEMPER, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,592 · see citing works
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548 · see citing works
Self-citationTtal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161 · see citing works
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899 · see citing works
Self-citationHigh-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768 · see citing works
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450 · see citing works
Self-citationCarfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332 · see citing works
Self-citationElotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505654 · Cited by 1,322 · see citing works
Self-citationLenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233 · see citing works
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A. M., Hulin, C., Benboubker, L., Garderet, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114138 · Cited by 1,155 · see citing works
Self-citationLenalidomide after Stem-Cell Transplantation for Multiple Myeloma
McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114083 · Cited by 1,147 · see citing works
Self-citationTargeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117 · see citing works
Self-citationOral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Moreau, P., Masszi, T., Grzasko, N., Bahlis, N. J., Hansson, M., Pour, L., Sandhu, I., Ganly, P., Baker, B. W., Jackson, S. R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516282 · Cited by 1,060 · see citing works
Self-citationRajkumar, S. V., Jacobus, S., Callander, N. S., Fonseca, R., Vesole, D. H., Williams, M. E., Abonour, R., Siegel, D. S., Katz, M., & Greipp, P. R. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70284-0 · Cited by 933 · see citing works
Facon, T. T. F., Mary, J., Hulin, C., Benboubker, L., Attal, M., Pegourié, B., Renaud, M., Harousseau, J. L., Guillerm, G., Chaleteix, C., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61537-2 · Cited by 865 · see citing works
Self-citationRichardson, P. G., Weller, E., Lonial, S., Jakubowiak, A. J., Jagannath, S., Raje, N. S., Avigan, D. E., Xie, W., Ghobrial, I. M., Schlossman, R. L., et al. (2010) · Blood · doi:10.1182/blood-2010-02-268862 · Cited by 861 · see citing works
Self-citationLonial, S., Weiss, B. M., Usmani, S. Z., Singhal, S., Chari, A., Bahlis, N. J., Belch, A., Krishnan, A., Vescio, R. A., Mateos, M. V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01120-4 · Cited by 854 · see citing works
Self-citationSonneveld, P., Schmidt-Wolf, I. G. H., van der Holt, B., el Jarari, L., Bertsch, U., Salwender, H., Zweegman, S., Vellenga, E., Broyl, A., Blau, I. W., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.6820 · Cited by 824 · see citing works
Cavo, M., Tacchetti, P., Patriarca, F. F., Petrucci, M. T., Pantani, L., Galli, M., Raimondo, F. D., Crippa, C., Zamagni, E., Palumbo, A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61424-9 · Cited by 815 · see citing works
Palumbo, A., Bringhen, S., Caravita, T., Merla, E., Capparella, V., Callea, V., Cangialosi, C., Grasso, M., Rossini, F., Galli, M., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68338-4 · Cited by 806 · see citing works
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402551 · Cited by 793 · see citing works
Self-citationAutologous Transplantation and Maintenance Therapy in Multiple Myeloma
Palumbo, A., Cavallo, F., Gay, F., Di Raimondo, F., Ben Yehuda, D., Petrucci, M. T., Pezzatti, S., Caravita, T., Cerrato, C., Ribakovsky, E., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402888 · Cited by 778 · see citing works
Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
Palumbo, A. P., Hájek, R., Delforge, M., Kropff, M. H., Petrucci, M. T., Catalano, J. V., Gisslinger, H., Wiktor-Jędrzejczak, W., Zodelava, M., Weisel, K. C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112704 · Cited by 739 · see citing works
Harousseau, J., Attal, M., Avet‐Loiseau, H., Marit, G., Caillot, D., Mohty, M., Lenain, P., Hulin, C., Facon, T. T. F., Casassus, P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.9158 · Cited by 529 · see citing works
Self-citationPaiva, B., Vídriales, M., Cerveró, J., Mateo, G., Pérez, J. J., Montalbán, M.-Á., Sureda, A. M., Montejano, L., Gutierrez, N. C., de Coca, A. G., et al. (2008) · Blood · doi:10.1182/blood-2008-05-159624 · Cited by 475 · see citing works
Palumbo, A., Bringhen, S., Rossi, D., Cavalli, M., Larocca, A., Ria, R., Offidani, M., Patriarca, F., Nozzoli, C., Guglielmelli, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.8216 · Cited by 423 · see citing works
Rawstron, A. C., Child, J. A., Tute, R. M. D., Davies, F. E., Gregory, W. M., Bell, S., Szubert, A. J., Navarro-Coy, N. C., Drayson, M. T., Feyler, S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.2119 · Cited by 414 · see citing works
Hulin, C., Facon, T. T. F., Rodon, P., Pegourié, B., Benboubker, L., Doyen, C., Dib, M., Guillerm, G., Salles, B., Eschard, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.0948 · Cited by 379 · see citing works
Self-citationDimopoulos, M. A., Chen, C. L., Spencer, A. G., Niesvizky, R., Attal, M., Stadtmauer, E. A., Petrucci, M. T., Yu, Z., Olesnyckyj, M., Zeldis, J. B., et al. (2009) · Leukemia · doi:10.1038/leu.2009.147 · Cited by 363 · see citing works
Self-citationGay, F., Oliva, S., Petrucci, M. T., Conticello, C., Catalano, L., Corradini, P., Siniscalchi, A., Magarotto, V., Pour, L., Carella, A. M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00389-7 · Cited by 311 · see citing works
Roussel, M., Lauwers‐Cancès, V., Robillard, N., Hulin, C., Leleu, X. P., Benboubker, L., Marit, G., Moreau, P., Pegourié, B., Caillot, D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8164 · Cited by 264 · see citing works
Self-citationWijermans, P., Schaafsma, M. R., Termorshuizen, F., Ammerlaan, R., Wittebol, S. H., Sinnige, H. A. M., Zweegman, S., Kooy, M. V. M., van der Griend, R., Lokhorst, H. M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.1610 · Cited by 259 · see citing works
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.
Waage, A., Gimsing, P., Fayers, P., Abildgaard, N., Ahlberg, L., Björkstrand, B., Carlson, K., Dahl, I., Forsberg, K., Gulbrandsen, N., et al. (2010) · Blood · doi:10.1182/blood-2009-08-237974 · Cited by 242 · see citing works
Dong, C., & Hemminki, K. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1998 · Cited by 179 · see citing works
Dong, C., & Hemminki, K. (2001) · British Journal of Cancer · doi:10.1038/sj.bjc.6691998 · Cited by 176 · see citing works
Beksaç, M., Haznedar, R., Firatli‐Tuglular, T., Özdoğu, H., Aydoğdu, İ., Konuk, N., Sucak, G. T., Kaygusuz, I., Karakuş, S., Kaya, E., et al. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01524.x · Cited by 142 · see citing works
Current Trends in Autologous Stem-Cell Transplantation for Myeloma in the Era of Novel Therapies
Moreau, P., Avet‐Loiseau, H., Harousseau, J., & Attal, M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.5878 · Cited by 130 · see citing works
Self-citationCurrent strategies for treatment of relapsed/refractory multiple myeloma
Laubach, J. P., Voorhees, P. M., Hassoun, H., Jakubowiak, A. J., Lonial, S., & Richardson, P. G. G. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.882764 · Cited by 67 · see citing works
Self-citationAssessment of minimal residual disease in myeloma and the need for a consensus approach
Rawstron, A. C., Paiva, B., & Stetler‐Stevenson, M. (2015) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21272 · Cited by 45 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [21]21. Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexa- methasone combination therapy in pa- tients with newly diagnosed multiple my- eloma. Blood 2010; 116: 679-86.
Cited by
Sorted by citations
Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016
Cowan, A. J., Allen, C., Barac, A., Basaleem, H., Bensenor, I., Curado, M. P., Foreman, K., Gupta, R., Harvey, J., Hosgood, H. D., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2128 · Cited by 631 · see citing works
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld, P., Dimopoulos, M. A., Boccadoro, M., Quach, H., Ho, P. J., Beksac, M., Hulin, C., Antonioli, E., Leleu, X., Mangiacavalli, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2312054 · Cited by 599 · see citing works
Self-citationMultiple myeloma: 2024 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2024) · American Journal of Hematology · doi:10.1002/ajh.27422 · Cited by 534 · see citing works
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma
Richardson, P. G., Jacobus, S. J., Weller, E. A., Hassoun, H., Lonial, S., Raje, N. S., Medvedova, E., McCarthy, P. L., Libby, E. N., Voorhees, P. M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204925 · Cited by 487 · see citing works
Self-citationThe multiple myelomas — current concepts in cytogenetic classification and therapy
Kumar, S. K., & Rajkumar, S. V. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0018-y · Cited by 302 · see citing works
Joseph, N. S., Kaufman, J. L., Dhodapkar, M. V., Hofmeister, C. C., Almaula, D. K., Heffner, L. T., Gupta, V. A., Boise, L. H., Lonial, S., & Nooka, A. K. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02515 · Cited by 238 · see citing works
Rosiñol, L., Oriol, A., Rios, R., Sureda, A., Blanchard, M. J., Hernández, M. T., Martínez-Martínez, R., Moraleda, J. M., Jarque, I., Bargay, J., et al. (2019) · Blood · doi:10.1182/blood.2019000241 · Cited by 219 · see citing works
Gooding, S., Ansari-Pour, N., Towfic, F., Ortiz Estévez, M., Chamberlain, P. P., Tsai, K.-T., Flynt, E., Hirst, M., Rozelle, D., Dhiman, P., et al. (2021) · Blood · doi:10.1182/blood.2020007081 · Cited by 172 · see citing works
San-Miguel, J., Avet-Loiseau, H., Paiva, B., Kumar, S., Dimopoulos, M. A., Facon, T., Mateos, M.-V., Touzeau, C., Jakubowiak, A., Usmani, S. Z., et al. (2022) · Blood · doi:10.1182/blood.2020010439 · Cited by 153 · see citing works
Self-citationGenomic Classification and Individualized Prognosis in Multiple Myeloma
Maura, F., Rajanna, A. R., Ziccheddu, B., Poos, A. M., Derkach, A., Maclachlan, K., Durante, M., Diamond, B., Papadimitriou, M., Davies, F., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01277 · Cited by 131 · see citing works
Treatment options for triple-class refractory multiple myeloma.
Mikhael, J. (2020) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2019.09.621 · Cited by 126 · see citing works
Gullà, A., Hideshima, T., Bianchi, G., Fulciniti, M., Kemal Samur, M., Qi, J., Tai, Y.-T., Harada, T., Morelli, E., Amodio, N., et al. (2018) · Leukemia · doi:10.1038/leu.2017.334 · Cited by 102 · see citing works
Self-citationLiu, J., Song, T., Zhou, W., Xing, L., Wang, S., Ho, M., Peng, Z., Tai, Y.-T., Hideshima, T., Anderson, K. C., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0205-y · Cited by 83 · see citing works
Self-citationCosta, B. A., Mouhieddine, T. H., Ortiz, R. J., & Richter, J. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104040 · Cited by 18 · see citing works
Special considerations for the diagnosis and treatment of invasive pulmonary aspergillosis
McCarthy, M. W., & Walsh, T. J. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1340835 · Cited by 8 · see citing works
- Authors
- Attal, M., Lauwers-Cances, V., Hulin, C., Leleu, X., Caillot, D., Escoffre, M., Arnulf, B., Macro, M., Belhadj, K., Garderet, L., Roussel, M., Payen, C., Mathiot, C., Fermand, J. P., Meuleman, N., Rollet, S., Maglio, M. E., Zeytoonjian, A. A., Weller, E. A., Munshi, N., Anderson, K. C., Richardson, P. G., Facon, T., Avet-Loiseau, H., Harousseau, J.-L., & Moreau, P.
- Affiliations
- Centre Hospitalier Universitaire de Toulouse (FR)
- Institut Jules Bordet (BE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-04-06
- Volume
- 376
- Issue
- 14
- Pages
- 1311-1320
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6201242
- OpenAlex
- W2604776612
- Semantic Scholar
- ca33f8e918b8f2db1c5d2884eb02b3a862664dc6
- Cited by
- 1,257
- References
- 41
- Citations by year
- 2026: 80 · 2025: 119 · 2024: 116 · 2023: 145 · 2022: 138 · 2021: 174 · 2020: 191 · 2019: 119 · 2018: 110 · 2017: 58 · 2013: 1 · 2012: 1
- FWCI
- 100.39
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Sanofi
- Gilead Sciences
- Celgene
- Agence Nationale de la Recherche (ANR-11-PHUC-0001)
- National Cancer Institute (P01CA155258)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Amyloidosis: Diagnosis, Treatment, Outcomes
- Keywords
- multiple myeloma, lenalidomide, bortezomib, dexamethasone, autologous stem cell transplantation, high-dose melphalan, progression-free survival, complete response, minimal residual disease, neutropenia, elderly patients, newly diagnosed multiple myeloma, consolidation therapy, maintenance therapy, overall survival, treatment toxicity, secondary malignancies
- MeSH terms
- Bortezomib, Lenalidomide, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Dexamethasone, Female, Humans, Male, Middle Aged, Multiple Myeloma, Thalidomide, Transplantation, Autologous, Salvage Therapy, Disease-Free Survival, Stem Cell Transplantation, Kaplan-Meier Estimate, Maintenance Chemotherapy, Induction Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
